Important milestone for cancer patients in Norway:
Åslaug Helland, oncologist and group leader in the department will lead a new center for clinical treatment research that receives major funding from The Research Council of Norway and the Norwegian Cancer Society:
The Research Council of Norway and the Norwegian Cancer Society have allocated 128 mill. NOK for a Centre for Clincial Treatment Research for treatment of cancer.
"This funding is an important contribution to Norwegian cancer research and will ensure that more patients will be included into clinical trials. The aim is new and better treatment alternatives for hard-to-treat cancers. We will develop next generation diagnostics and treatment for increased overall survival and quality of life for cancer patients all over Norway" says Åslaug Helland, leader of the centre.
Conferral ceremony 30. September 2021
Tine Alver and Zhi Zhao receiving their PhD ceremonial diplomas
Tine Alver and Zhi Zhao from our department, received their PhD ceremonial diplomas in the University's ceremonial hall, the Aula, on 30. September 2021.
Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, Falk RS, Geitvik GA, Gilje B, Gravdehaug B, Heie A, Janssen E, Kiserud CE, Kursetgjerde T, Langerød A, Lømo J, Mannsåker B, Mortensen E, Olsson P, Porojnicu AC, Raj SX, Roe OD, Russnes HEG, Skjerven HK, Songe-Møller Set al.(2025) Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives Clin Breast Cancer(in press) DOI 10.1016/j.clbc.2025.04.011, PubMed 40348620
Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A(2025) Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access Future Oncol, 1-8(in press) DOI 10.1080/14796694.2025.2501523, PubMed 40340714
Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK(2025) Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50 ESMO Open, 10(5), 105073(in press) DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908